Fujifilm Diosynth Biotechnologies Expands Cell-Culture Capacity - - BioPharm International


Fujifilm Diosynth Biotechnologies Expands Cell-Culture Capacity

Fujifilm Diosynth Biotechnologies will expand its cell-culture manufacturing capabilities by adding two, 2000-L single-use bioreactors. One each of these is being installed at the company's sites in Research Triangle Park (RTP), NC, USA and Billingham, UK.

The new reactors will complement the range of vessels at both sites, adding further flexibility for customer requirements. Each site currently operates 1000-L single-use bioreactors with 250-L to 1000-L operating volumes, with an additional 200-L single-use bioreactor in the UK, and a 2000-L stainless steel train in RTP, which has been in place for a number of years manufacturing a range of products.

"The addition of these two new bioreactors will meet the demand we are seeing for a 2000-L platform, and offer a cost-effective, low-risk route to market through 'scaling-out' from early phase to commercial manufacture," said Steve Bagshaw, CEO Fujifilm Diosynth Biotechnologies, in a press release. The new bioreactors are expected to be operational by November 2014 in the US and in the UK in January 2015.

Source: Fujifilm Diosynth Biotechnologies

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here